Gedea Biotech completes VVC-2025 study and advances product expansion to treat vaginal fungal infections
Gedea Biotech today announced continued progress in its strategy to expand the CE-marked indications for pHyph to include the treatment of vulvovaginal candidiasis (VVC), commonly known as vaginal fungal infection.
The company has completed the clinical study, VVC-2025 and continues to advance the review process for expanding the existing CE-mark to include the treatment of VVC. The first-in-class product, pHyph, is already approved for the treatment of vaginal bacterial infections (bacterial vaginosis, BV) and to maintain a healthy microbiome.
VVC-2025 is a randomised, controlled study